6 commercial payer policies list C9782. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
6 policies from 6 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of C9782 |
|---|---|---|
| Autologous Skeletal Myoblast/Mononuclear Bone Marrow Cell Transplantation | Aug 30, 2023 | Covered |
| Policy | Effective | Status of C9782 |
|---|---|---|
| Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia | Jan 1, 2026 | Covered |
| Policy | Effective | Status of C9782 |
|---|---|---|
| Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia | Jan 1, 2026 | Covered |
| Policy | Effective | Status of C9782 |
|---|---|---|
| Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia | Jan 1, 2026 | Covered |
| Policy | Effective | Status of C9782 |
|---|---|---|
| Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia | Jan 1, 2026 | Covered |
| Policy | Effective | Status of C9782 |
|---|---|---|
| Cell-based Therapies for Cardiac and Peripheral Arterial Disease | May 15, 2026 | Not covered |